|Bid||9.84 x 2900|
|Ask||10.00 x 4000|
|Day's Range||9.84 - 10.02|
|52 Week Range||8.46 - 12.40|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||6.44|
|Earnings Date||Nov 06, 2023 - Nov 10, 2023|
|Forward Dividend & Yield||0.48 (4.89%)|
|Ex-Dividend Date||Aug 23, 2023|
|1y Target Est||14.78|
Subscribe to Yahoo Finance Plus to view Fair Value for VTRS
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.
If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your financial position. Three stocks that pay high yields and that could help accomplish this include Viatris (NASDAQ: VTRS), Verizon Communications (NYSE: VZ), and Altria Group (NYSE: MO). Generic and branded drugmaker Viatris has the potential to make for a stable long-term investment.